CFM
QNCX icon

Catalyst Funds Management’s Quince Therapeutics QNCX Stock Holding History

Catalyst Funds Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-150
Closed -$3.04K – 838
2026
Q1 		$3.04K Buy
+150
New +$30.1K ﹤0.01% 584

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Catalyst Funds Management's QNCX Position: Q2 2026 in Review

Catalyst Funds Management sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 150 shares — an estimated $3.04K sold.

Catalyst Funds Management first reported a position in QNCX in Q1 2026 and held it in 1 quarter. The position peaked at $3.04K in Q1 2026. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Catalyst Funds Management reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 150 Quince Therapeutics shares in Q2 2026, an estimated $3.04K.
  • Catalyst Funds Management first reported a position in Quince Therapeutics in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's Quince Therapeutics position peaked at $3.04K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.